PIPELINE AND CLINICAL PROGRAMS

A POWERFUL RESEARCH AND DEVELOPMENT ENGINE

Our pipeline is powered by end-to-end research and development capabilities. The Research team discovers promising new drug compounds. From there, Global Development brings these investigational candidates through the full clinical development process, from trial design to study execution and lifecycle management. Our product portfolio reflects the true collaborative spirit of Regeneron.

Explore the Regeneron clinical pipeline

Select therapeutic area(s):
Select phase(s):
Select collaborator(s):

Displaying item

Clear Filters

Phase 1

  • REGN6569
    GITR Antibody Solid tumors
  • ODRONEXTAMAB
    CD20 X CD3 Antibody Certain B-cell malignancies
  • REGN4018
    MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
  • REGN5459
    BCMA X CD3 Antibody Multiple myeloma
  • REGN5678
    PSMA X CD28 Antibody Prostate cancer
  • REGN5093
    MET X MET Antibody MET-altered advanced non-small cell lung cancer (NSCLC)
  • REGN5093-M114
    MET X MET Antibody MET overexpressing advanced cancer
  • REGN7257
    IL-2Rg Antibody Aplastic anemia
  • CASIRIVIMAB AND IMDEVIMAB6
    SARS-CoV-2 Virus Multi-Antibody Therapy COVID-19 multi-dose safety study
  • REGN5381
    NPR1 Agonist Antibody Heart failure
  • FIANLIMAB
    LAG-3 Antibody Solid tumors, advanced hematologic malignancies
  • REGN5668
    MUC16 x CD28 Ovarian cancer
  • REGN7075
    EGFR x CD28 Solid tumors
  • REGN6490
    IL-36R Antibody Palmo-plantar pustulosis
  • ALN-HSD5
    HSD17B13 RNAi Therapeutic Nonalcoholic steatohepatitis
  • NTLA-20014
    CRISPR/Cas9 Hereditary transthyretin amyloidosis with polyneuropathy
  • REGN9933
    Antibody to Factor XI Thrombosis

Phase 2

  • AFLIBERCEPT3
    VEGF-Trap High-dose (8 mg) for wet age-related macular degeneration (AMD)
  • CEMIPLIMAB1
    PD-1 Antibody Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC, second-line cervical cancer
  • ODRONEXTAMAB
    CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma
  • REGN5458
    BCMA X CD3 Antibody Multiple myeloma
  • SARILUMAB1
    IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
  • DUPILUMAB1
    IL-4R Antibody Peanut allergy, grass allergy
  • EVINACUMAB
    ANGPTL-3 Antibody Acute pancreatitis prevention
  • REGN4461
    LEPR Agonist Antibody Generalized lipodystrophy
  • GARETOSMAB
    Activin-A Antibody Fibrodysplasia ossificans progressiva (FOP)
  • CEMDISIRAN5
    C5 siRNA Therapeutic Immunoglobulin A nephropathy
  • POZELIMAB
    C5 Antibody CD55 deficient protein-losing enteropathy
  • POZELIMAB + CEMDISIRAN5
    CD5 Antibody + C5 siRNA Therapeutic Paroxysmal nocturnal hemoglobinuria
  • CASIRIVIMAB AND IMDEVIMAB6
    SARS-CoV-2 Virus Multi-Antibody Therapy Treatment in non-hospitalized COVID-19 patients

Phase 3

  • AFLIBERCEPT3
    VEGF-Trap Retinopathy of prematurity (ROP), high-dose formulation (8 mg) for wet age-related macular degeneration (AMD) and diabetic macular edema (DME)
  • CEMIPLIMAB1
    PD-1 Antibody First-line non-small cell lung cancer (NSCLC) chemo combination, second-line cervical cancer, adjuvant CSCC
  • DUPILUMAB1
    IL-4R Antibody Atopic dermatitis in pediatric patients 6 mo.–5 y.o; hand and foot atopic dermatitis; eosinophilic esophagitis (EoE) in adults, adolescents, and pediatrics; chronic obstructive pulmonary disease (COPD); bullous pemphigoid; prurigo nodularis; chronic spontaneous urticaria; allergic bronchopulmonary aspergillosis; chronic inducible urticaria; chronic sinusitis without nasal polyposis; allergic fungal rhinosinusitis
  • CASIRIVIMAB AND IMDEVIMAB6
    SARS-CoV-2 Virus Multi-Antibody Therapy Hospitalized and non-hospitalized COVID-19 treatment, COVID-19 prevention
  • ALIROCUMAB
    PCSK9 Antibody Heterozygous familial hypercholesterolemia (HeFH) in pediatrics
  • FASINUMAB2
    NGF Antibody Osteoarthritis pain of the knee or hip
  • ITEPEKIMAB1
    IL-33 Antibody Chronic obstructive pulmonary disease (COPD)
  • REGN5713-5714-5715
    Bet v 1 Multi-Antibody Therapy Birch allergy
  • REGN1908-1909
    Fel d 1 Multi-Antibody Therapy Cat allergy
  • POZELIMAB + CEMDISIRAN5
    CD5 Antibody + C5 siRNA Therapeutic Myasthenia gravis

No results found. Please adjust your filter selection and try again.

1Sanofi

2Teva and Mitsubishi Tanabe

3Bayer

4Intellia

5Alnylam

6Roche

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Regeneron's therapeutic research areas

Scientific trailblazers

Following the science leads to unexpected breakthroughs and diverse areas of study —from ophthalmology to cancer to inflammation to pain to cardiovascular disease.

Our Current Research

Putting antibodies in action

Discover our clinical trials

Learn more about our clinical trials and find one near you.

Find Trials

Back to top